MGMT and central nervous system cancer: Since the MGMT promoter methylation status has been proven to be an independent prognostic and predictive marker in glioma regardless of the WHO classification or chemotherapy regimen [3–5, 23, 24], prediction of the MGMT promoter methylation status using 18F-FDG-PET radiomics may have great clinical potential.